Hypoxia inducible factor down-regulation, cancer and cancer stem cells (CSCs): ongoing success stories
- Others:
- Institut de Chimie de Nice (ICN) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)
- UFR Biomédicale des Saints-Pères ; Université Paris Descartes - Paris 5 (UPD5)
- Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques ; Université de Nantes (UN)
Description
In cancers, hypoxia inducible factor 1 (HIF-1) is an over-expressed transcription factor, which regulates a large set of genes involved in tumour vascularization, metastases, and cancer stem cells (CSCs) formation and self-renewal. This protein has been identified as a relevant target in oncology and several HIF-1 modulators are now marketed or in advanced clinical trials. The purpose of this review is to summarize the advances in the understanding of its regulation and its inhibition, from the medicinal chemist point of view. To this end, we selected in the recent literature relevant examples of "hit" compounds, including small-sized organic molecules, pseudopeptides and nano-drugs, exhibiting in vitro and/or in vivo both anti-HIF-1 and anti-tumour activities. Whenever possible, a particular emphasis has been dedicated to compounds that selectively target CSCs.
Abstract
International audience
Additional details
- URL
- https://hal.science/hal-01589485
- URN
- urn:oai:HAL:hal-01589485v1
- Origin repository
- UNICA